PRESS RELEASE published on 02/22/2023 at 18:05, 3 years 3 months ago Abivax annonce le succès d’un financement cross-over sursouscrit de 130 millions d’euros au prix du marché, par des investisseurs américains et européens de premier plan
PRESS RELEASE published on 02/17/2023 at 08:00, 3 years 4 months ago Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
PRESS RELEASE published on 02/17/2023 at 08:00, 3 years 4 months ago Abivax: Le Dr. Sheldon Sloan, M.D., est nommé Directeur Médical d’Abivax
PRESS RELEASE published on 02/14/2023 at 18:00, 3 years 4 months ago Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO
PRESS RELEASE published on 02/14/2023 at 18:00, 3 years 4 months ago Abivax présentera lors du 18ème Congrès de l’ECCO des données issues d’échantillons sanguins et de biopsies rectales de patients atteints de RCH et traités avec obefazimod
PRESS RELEASE published on 01/31/2023 at 18:00, 3 years 4 months ago ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANES) WITH A NOMINAL VALUE OF EUR 24,999,975.99
PRESS RELEASE published on 01/31/2023 at 18:00, 3 years 4 months ago ABIVAX: AVIS AUX PORTEURS D’OBLIGATIONS CONVERTIBLES/ECHANGEABLES EN ACTIONS NOUVELLES ET/OU EXISTANTES (OCEANES) D’UN MONTANT NOMINAL DE 24 999 975,99 EUROS
PRESS RELEASE published on 01/30/2023 at 18:00, 3 years 4 months ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
PRESS RELEASE published on 01/30/2023 at 18:00, 3 years 4 months ago ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2022
PRESS RELEASE published on 01/05/2023 at 08:00, 3 years 5 months ago Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action
Published on 06/20/2026 at 01:00, 1 day 20 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 21 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 17 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 20 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 20 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 1 day ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 15 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 2 days 1 hour ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 2 days 1 hour ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 2 days 2 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 2 days 2 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days 2 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days 2 hours ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 2 days 2 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
